Compound Kushen Injection Reduces Severe Toxicity and Symptom Burden Associated With Curative Radiotherapy in Patients With Lung Cancer

作者全名："Liu, Jie; Yu, Qingxi; Wang, Xin Shelley; Shi, Qiuling; Wang, Jun; Wang, Fan; Ren, Simeng; Jin, Jiayue; Han, Baojin; Zhang, Wenzheng; Su, Xueyao; Yuan, Shuanghu; Lin, Hongsheng"

作者地址："[Liu, Jie; Ren, Simeng; Zhang, Wenzheng; Lin, Hongsheng] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Oncol, Beijing, Peoples R China; [Yu, Qingxi] Shandong Canc Hosp, Dept Radiat Oncol, Jinan, Shandong, Peoples R China; [Wang, Xin Shelley] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX USA; [Shi, Qiuling; Su, Xueyao] Chongqing Med Univ, Sch Publ Hlth, Chongqing, Peoples R China; [Wang, Jun] Hebei Tumor Hosp, Dept Radiat Oncol, Shijiazhuang, Hebei, Peoples R China; [Wang, Fan] Anhui Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, He Fei Shi, Anhui, Peoples R China; [Jin, Jiayue; Han, Baojin] Beijing Univ Chinese Med, Beijing, Peoples R China; [Lin, Hongsheng] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Oncol, 5 Bei Xian Ge St, Beijing 100053, Peoples R China; [Yuan, Shuanghu] Shandong Canc Hosp, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250000, Shandong, Peoples R China"

通信作者："Lin, HS (通讯作者)，China Acad Chinese Med Sci, Guanganmen Hosp, Dept Oncol, 5 Bei Xian Ge St, Beijing 100053, Peoples R China.; Yuan, SH (通讯作者)，Shandong Canc Hosp, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250000, Shandong, Peoples R China."

来源：JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001063796600008

JCR分区：Q1

影响因子：14.8

年份：2023

卷号：21

期号：8

开始页：821

结束页：+

文献类型：Article

关键词：　

摘要："Background: Radiotherapy (RT) causes adverse events for which there are no effective treatments. This study investigated the clinical benefits of compound Kushen injection (CKI) in managing radiation injury in patients with lung cancer. Methods: A multicenter, open label, randomized clinical trial randomly assigned patients with lung cancer to receive either CKI (20 mL/d for at least 4 weeks) integrated with curative RT (RT + CKI group; n=130) or RT alone (control group; n=130). The primary outcome was the incidence of grade =2 radiation induced lung injury (RILI) in the lungs, esophagus, or heart. Secondary outcomes included patient-reported symptoms, quality of life, objective response rate (ORR), and toxic effects. Results: During the 16-week trial, the RT + CKI group had a significantly lower incidence of grade =2 RT-related injury than the control group (12.3% [n=16] vs 23.1% [n=30]; P=.02). Compared with the control group, the RT + CKI group experienced a significant decrease in moderate-to-severe symptoms of fatigue, cough, and pain (P<.001 for the treatment and time interaction term); significantly less physical symptom interference (P=.01); and significantly better quality of life by the end of the trial (P<.05). No statistically significant difference in ORR was found. Adverse reactions associated with CKI were rare. Conclusions: This study demonstrated low toxicity of CKI and its effectiveness in patients with lung cancer in reducing the incidence of grade =2 RILI and symptom burden, improving patients' quality of life."

基金机构：　

基金资助正文：